European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Corona Accelerated R&D in Europe

Description du projet

Un consortium européen pour la prévention, l’immunothérapie et la découverte médicamenteuse en matière de coronavirus

La pandémie de coronavirus associée au syndrome respiratoire aigu sévère 2 (SARS-CoV-2) représente la plus grande menace sanitaire du siècle. Le projet CARE, financé par l’UE, constitue une coalition de 37 institutions académiques, entreprises pharmaceutiques et organismes de recherche à but non lucratif. Les principaux objectifs du consortium sont de développer des outils thérapeutiques pour établir une réponse d’urgence à la pandémie actuelle de SARS-CoV-2, via le repositionnement des médicaments, et répondre à de futures épidémies à travers la découverte de médicaments et d’anticorps neutralisant les virus. L’efficacité et l’innocuité des médicaments thérapeutiques candidats seront testées in vitro et sur des modèles animaux. En outre, le projet permettra de produire des anticorps monoclonaux neutralisant les virus et d’identifier des marqueurs immunitaires. Les candidats les plus prometteurs seront soumis à des essais cliniques de phases 1 et 2 chez l’homme.

Objectif

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situation Report of March 28th 2020, 571,659 patients were diagnosed with Coronavirus Disease 2019 (COVID-19) and 26,493 deaths were reported globally. The wide spectrum of clinical symptoms, disease severity in high risk individuals, transmission efficiency and high mortality, raises an immediate need for vaccines or therapeutics. Given that the viral variant is new in the human population and emerged less than 4 months ago, there is no vaccine or approved therapies. The Corona Accelerated R&D in Europe (CARE) consortium is a coalition of 37 globally renowned academic institutions, pharmaceutical companies and non-profit research organizations who have committed to rapidly and efficiently address this emergent health threat, and the main objectives are: the development of therapeutics (i) to provide an emergency response towards the current COVID-19 pandemic by drug repositioning and (ii) to address the current and/or future coronavirus outbreaks by broad-spectrum small-molecule drug discovery and/or virus-neutralizing antibody discovery. To achieve this, a collection of repurposed drugs, focused libraries and small molecule libraries will be screened against SARS-CoV-2, other emerging SARS-CoV-2 clades and related coronavirus genera in phenotypic or target-based assays. A focused medicinal chemistry campaign will identify small-molecule hits, and Absorption, Distribution, Metabolism and Excretion (ADME), pharmacokinetic/pharmacodynamic (PK/PD), potency and safety of these therapeutic candidates will be assessed in vitro and in animal models. Virus-neutralizing monoclonal antibodies will be generated and further characterized. Immune markers will be identified contributing to the host immune responses to SARS-CoV-2 infections, and the correlation with clinical and virological outcomes will be determined. Finally, lead candidates will be advanced into Phase1 and Phase 2 clinical trials in humans. With this reactive response, the CARE consortium is dedicated to win the fight against coronavirus.

Coordinateur

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contribution nette de l'UE
€ 6 630 753,05
Adresse
RUE DE TOLBIAC 101
75654 Paris
France

Voir sur la carte

Région
Ile-de-France Ile-de-France Paris
Type d’activité
Research Organisations
Liens
Coût total
€ 8 084 160,05

Participants (42)